Drug Profile
Tozadenant - Acorda Therapeutics
Alternative Names: A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Acorda Therapeutics
- Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders; Parkinson's disease
Most Recent Events
- 20 Nov 2017 Biotie Therapies terminates a phase I trial in Liver disorders (In volunteers) in USA based on previously disclosed agranulocytosis and associated serious adverse events (PO) (NCT03212313)
- 20 Nov 2017 Biotie Therapies terminates the phase III TOZ-PD trial in Parkinson's disease (Adjunctive treatment) in USA, Canada, Spain, Germany, Czech Republic due to previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT02453386)
- 20 Nov 2017 Biotie Therapies terminates a phase I trial in Healthy volunteers in Canada based on previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT03200080)